72
Participants
Start Date
November 30, 2016
Primary Completion Date
February 21, 2019
Study Completion Date
July 18, 2019
HeartMate II (HMII)
Left Ventricular Assist Device
Warfarin
(INR Target 2.0-2.5, median 2.25, per standard of patient care)
acetylsalicylic acid (ASA) therapy
(81mg/day)
New York Presbyterian Hospital/Columbia University, New York
Montefiore Medical Center, The Bronx
Westchester Medical Center, Valhalla
Stony Brook University Medical Center, Stony Brook
University of Rochester Medical Center, Rochester
Thomas Jefferson University Hospital, Philadelphia
Temple University Hospital, Philadelphia
Washington Hospital Center, Washington D.C.
University of North Carolina at Chapel Hill, Chapel Hill
Palmetto Health Richland, Columbia
Piedmont Hospital, Atlanta
Shands at the University of Florida, Gainesville
Florida Hospital, Orlando
University of Alabama Hospital at Birmingham (UAB), Birmingham
Baptist Memorial Hospital, Memphis
Ohio State University, Columbus
Christ Hospital, Cincinnati
St. Vincent Hospital, Indianapolis
Henry Ford Hospital, Detroit
St. Luke's Medical Center, Milwaukee
University of Minnesota Medical Center Fairview, Minneapolis
Mayo Clinic, Rochester
Kansas University Medical Center, Kansas City
Ochsner Medical Center, New Orleans
Integris Baptist Medical Center, Oklahoma City
Baylor University Hospital, Dallas
Memorial Hermann, Houston
Seton Medical Center, Austin
Ronald Reagan UCLA Medical Center, Los Angeles
Sharp Memorial Hospital, San Diego
University of California at San Francisco, San Francisco
Providence St. Vincent, Portland
Tufts Medical Center, Boston
Institut de Cardiologie de Montreal (Montreal Heart Inst.), Montreal
Institut de Cardiologie de Quebec (Hôpital Laval), Québec
Lead Sponsor
Abbott Medical Devices
INDUSTRY